Adrenergic nervous system in heart failure : pathophysiology and therapy
Heart failure (HF), the leading cause of death in the western world, develops when a cardiac injury or insult impairs the ability of the heart to pump blood and maintain tissue perfusion. It is characterized by a complex interplay of several neurohormonal mechanisms that become activated in the syndrome to try and sustain cardiac output in the face of decompensating function. Perhaps the most prominent among these neurohormonal mechanisms is the adrenergic (or sympathetic) nervous system (ANS), whose activity and outflow are enormously elevated in HF. Acutely, and if the heart works properly, this activation of the ANS will promptly restore cardiac function. However, if the cardiac insult persists over time, chances are the ANS will not be able to maintain cardiac function, the heart will progress into a state of chronic decompensated HF, and the hyperactive ANS will continue to push the heart to work at a level much higher than the cardiac muscle can handle. From that point on, ANS hyperactivity becomes a major problem in HF, conferring significant toxicity to the failing heart and markedly increasing its morbidity and mortality. The present review discusses the role of the ANS in cardiac physiology and in HF pathophysiology, the mechanisms of regulation of ANS activity and how they go awry in chronic HF, methods of measuring ANS activity in HF, the molecular alterations in heart physiology that occur in HF, along with their pharmacological and therapeutic implications, and, finally, drugs and other therapeutic modalities used in HF treatment that target or affect the ANS and its effects on the failing heart.
Errataetall: | |
---|---|
Medienart: |
E-Artikel |
Erscheinungsjahr: |
2013 |
---|---|
Erschienen: |
2013 |
Enthalten in: |
Zur Gesamtaufnahme - volume:113 |
---|---|
Enthalten in: |
Circulation research - 113(2013), 6 vom: 30. Aug., Seite 739-53 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Lymperopoulos, Anastasios [VerfasserIn] |
---|
Links: |
---|
Anmerkungen: |
Date Completed 25.10.2013 Date Revised 17.03.2022 published: Print ErratumIn: Circ Res. 2016 Aug 5;119(4):e38. - PMID 27492843 Citation Status MEDLINE |
---|
doi: |
10.1161/CIRCRESAHA.113.300308 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM230438180 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM230438180 | ||
003 | DE-627 | ||
005 | 20231224084426.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231224s2013 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1161/CIRCRESAHA.113.300308 |2 doi | |
028 | 5 | 2 | |a pubmed24n0768.xml |
035 | |a (DE-627)NLM230438180 | ||
035 | |a (NLM)23989716 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Lymperopoulos, Anastasios |e verfasserin |4 aut | |
245 | 1 | 0 | |a Adrenergic nervous system in heart failure |b pathophysiology and therapy |
264 | 1 | |c 2013 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 25.10.2013 | ||
500 | |a Date Revised 17.03.2022 | ||
500 | |a published: Print | ||
500 | |a ErratumIn: Circ Res. 2016 Aug 5;119(4):e38. - PMID 27492843 | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Heart failure (HF), the leading cause of death in the western world, develops when a cardiac injury or insult impairs the ability of the heart to pump blood and maintain tissue perfusion. It is characterized by a complex interplay of several neurohormonal mechanisms that become activated in the syndrome to try and sustain cardiac output in the face of decompensating function. Perhaps the most prominent among these neurohormonal mechanisms is the adrenergic (or sympathetic) nervous system (ANS), whose activity and outflow are enormously elevated in HF. Acutely, and if the heart works properly, this activation of the ANS will promptly restore cardiac function. However, if the cardiac insult persists over time, chances are the ANS will not be able to maintain cardiac function, the heart will progress into a state of chronic decompensated HF, and the hyperactive ANS will continue to push the heart to work at a level much higher than the cardiac muscle can handle. From that point on, ANS hyperactivity becomes a major problem in HF, conferring significant toxicity to the failing heart and markedly increasing its morbidity and mortality. The present review discusses the role of the ANS in cardiac physiology and in HF pathophysiology, the mechanisms of regulation of ANS activity and how they go awry in chronic HF, methods of measuring ANS activity in HF, the molecular alterations in heart physiology that occur in HF, along with their pharmacological and therapeutic implications, and, finally, drugs and other therapeutic modalities used in HF treatment that target or affect the ANS and its effects on the failing heart | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Research Support, N.I.H., Extramural | |
650 | 4 | |a Review | |
650 | 4 | |a adrenal glands | |
650 | 4 | |a adrenergic nervous system | |
650 | 4 | |a cardiac sympathetic nerve terminals | |
650 | 4 | |a catecholamine | |
650 | 4 | |a heart failure | |
650 | 4 | |a hyperactivation | |
650 | 4 | |a myocytes, cardiac | |
650 | 4 | |a receptors, adrenergic | |
650 | 4 | |a synaptic transmission | |
650 | 4 | |a β-blockers | |
650 | 7 | |a Adrenergic Antagonists |2 NLM | |
650 | 7 | |a Cardiovascular Agents |2 NLM | |
650 | 7 | |a Receptors, Adrenergic |2 NLM | |
700 | 1 | |a Rengo, Giuseppe |e verfasserin |4 aut | |
700 | 1 | |a Koch, Walter J |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Circulation research |d 1953 |g 113(2013), 6 vom: 30. Aug., Seite 739-53 |w (DE-627)NLM000001910 |x 1524-4571 |7 nnns |
773 | 1 | 8 | |g volume:113 |g year:2013 |g number:6 |g day:30 |g month:08 |g pages:739-53 |
856 | 4 | 0 | |u http://dx.doi.org/10.1161/CIRCRESAHA.113.300308 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 113 |j 2013 |e 6 |b 30 |c 08 |h 739-53 |